Physiomics plc (AIM: PYC) has secured a new £102,000 drug development modelling contract, taking the total value of contract awards announced since May 2026 to more than £970,000, exceeding the
Physiomics plc (AIM: PYC) has secured a new £102,000 drug development modelling contract, taking the total value of contract awards announced since May 2026 to more than £970,000, exceeding the
Physiomics plc (AIM: PYC) has secured a new £119,000 contract for drug development modelling while exploring additional commercial opportunities for its personalised dosing technology, including potential expansion into the US
Physiomics plc (AIM: PYC) reported its highest annual income since incorporation, with revenue and grant income rising 26.5% to £1.06 million in the year ended 30 June 2026.
The FTSE 100 closed 1.06% higher at 10,552.05 on Friday, while the FTSE 250 gained 1.13% to 24,213.78. The rebound followed a volatile week dominated by oil prices, inflation concerns
Physiomics Plc (AIM: PYC) has started turning a commercial reset into a run of new contract awards. After shareholder-driven board changes in April, the company carried out a strategic and
Small caps can spend years being valued mainly on what might happen next. A mineral explorer talks about targets, a developer talks about future production, and a specialist technology business
Small caps can spend years being valued mainly on what might happen next. A mineral explorer talks about targets, a developer talks about future production, and a specialist technology business
Small caps can spend years being valued mainly on what might happen next. A mineral explorer talks about targets, a developer talks about future production, and a specialist technology business
BBC: The Metropolitan Police is carrying out a criminal investigation into Reform UK over allegations it broke foreign funding laws, following a broadcast by Channel 4 News last week. An undercover
Physiomics plc (AIM: PYC) has secured new contracts worth more than £205,000, extending a strong run of commercial wins for the mathematical modelling, data science and biostatistics specialist.
London’s FTSE 100 outperformed global peers on Friday as defensive utilities and energy stocks helped offset wider market weakness driven by a sell-off in technology and semiconductor shares. The blue-chip
Poolbeg Pharma Plc (POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing